MC

778.6

-1.27%↓

ALV

261.7

+0.23%↑

SAF

205.7

+0.44%↑

BBVA

10.01

-0.79%↓

MC

778.6

-1.27%↓

ALV

261.7

+0.23%↑

SAF

205.7

+0.44%↑

BBVA

10.01

-0.79%↓

MC

778.6

-1.27%↓

ALV

261.7

+0.23%↑

SAF

205.7

+0.44%↑

BBVA

10.01

-0.79%↓

MC

778.6

-1.27%↓

ALV

261.7

+0.23%↑

SAF

205.7

+0.44%↑

BBVA

10.01

-0.79%↓

MC

778.6

-1.27%↓

ALV

261.7

+0.23%↑

SAF

205.7

+0.44%↑

BBVA

10.01

-0.79%↓

HomeStock ListBayer AG

Bayer AG

Open

Sector Finance

27.7 0.07

Overview

Share price change

24h

Current

Min

27.37

Max

28.24

Key metrics

By Trading Economics

Income

-2.7B

-4.6B

Sales

1.5B

12B

P/E

Sector Avg

30.837

12.185

EPS

1.85

Dividend yield

4.737

Profit margin

-44.179

EBITDA

818M

5.6B

Recommendations

By TipRanks

Rating Consensus

Neutral

12 Months Forecast

+18.22 upside

Dividends

By Dow Jones

Dividend Yield

Sector avg

4.74%

4.45%

Next earnings

14 May 2024

Market Stats

By TradingEconomics

Market Cap

-496M

27B

Previous open

27.63

Previous close

27.7

News Sentiment

By Acuity

40%

60%

81 / 315 Ranking in Finance

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Bayer AG chart

Related News

5 Mar 2024, 09:09 UTC

Earnings
Acquisitions, Mergers, TakeOvers

Bayer Decides Against Splitting Into Separate Units for Now -- 2nd Update

5 Mar 2024, 07:34 UTC

Earnings

Bayer Decides Against Splitting Up Company For Now -- Update

5 Mar 2024, 07:06 UTC

Acquisitions, Mergers, TakeOvers

Bayer Decides Against Splitting Up Company For Now

22 Mar 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ -2-

22 Mar 2024, 04:01 UTC

Top News

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ

5 Mar 2024, 10:23 UTC

Earnings

Bayer CEO Was Speaking on Call After Earnings

5 Mar 2024, 10:19 UTC

Market Talk
Earnings

Bayer's EPS Guidance Implies Consensus Downgrades -- Market Talk

5 Mar 2024, 09:55 UTC

Market Talk
Earnings

Bayer's 2024 Guidance Is Below Expectations -- Market Talk

5 Mar 2024, 09:44 UTC

Earnings

Bayer CEO: Time it Takes For Major Structural Change is Time We Don't Have, Need to Focus on Challenges

5 Mar 2024, 09:44 UTC

Earnings

Bayer CEO: There Has Been Calls From Major Shareholders For Break-Up, But They Understand Associated Drawbacks

5 Mar 2024, 08:52 UTC

Earnings

Bayer CEO: Exploring All Avenues to Remove Litigation Completely

5 Mar 2024, 08:51 UTC

Earnings

Bayer CEO: Strategy of Defence Against Litigation is Not Enough

5 Mar 2024, 08:44 UTC

Earnings

Bayer CEO: Need Total Focus on Overcoming Challenges

5 Mar 2024, 08:44 UTC

Earnings

Bayer CEO: Separation of Consumer Health Would Remove Steady Cash Flowing Business, Valutions Not Great

5 Mar 2024, 08:43 UTC

Earnings

Bayer CEO: IPO or Spin Would Require All-Hands on Deck For Long Period

5 Mar 2024, 08:43 UTC

Earnings

Bayer CEO: Material Challenges Remain

5 Mar 2024, 07:54 UTC

Market Talk
Earnings

Bayer Results, Strategy Update to Trigger Negative Share Reaction -- Market Talk

5 Mar 2024, 06:35 UTC

Earnings

Bayer Sees 2024 Free Cash Flow EUR2B-EUR3B

5 Mar 2024, 06:34 UTC

Earnings

Bayer Sees 2024 Core EPS EUR5.10-EPS EUR5.50

5 Mar 2024, 06:34 UTC

Earnings

Bayer Sees 2024 Pre-Items Ebitda EUR10.7B-EUR11.3B

5 Mar 2024, 06:34 UTC

Earnings

Bayer Sees 2024 Sales EUR47B-EUR49B

5 Mar 2024, 06:33 UTC

Earnings

Bayer: Analysts Saw 4Q Net Profit at EUR634M

5 Mar 2024, 06:33 UTC

Earnings

Bayer 4Q Net Pft EUR1.34B

5 Mar 2024, 06:33 UTC

Earnings

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 Mar 2024, 06:33 UTC

Earnings

Bayer 4Q Ebitda Before Special Items EUR3.02B

5 Mar 2024, 06:32 UTC

Earnings

Bayer: Analysts Saw 4Q Sales at EUR11.65B

5 Mar 2024, 06:32 UTC

Earnings

Bayer 4Q Sales EUR11.86B

5 Mar 2024, 06:32 UTC

Earnings

Bayer Sees 2024 Sales Roughly Level Year on Year

5 Mar 2024, 06:32 UTC

Earnings

Bayer: Structural Changes Remain An Option, But Not Now

5 Mar 2024, 06:31 UTC

Earnings

Bayer To Deliver Growth Through Customer Centricity and Innovation Speed, Annual Savings of EUR2B from 2026

Peer Comparison

Price change

Bayer AG forecast

Price Target

By TipRanks

18.22% upside

12 Months Forecast

Average 32.44 EUR  18.22%

High 45 EUR

Low 25 EUR

Based on 18 Wall Street analysts offering 12 month price targets for Bayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

18 ratings

1

Buy

16

Hold

1

Sell

Technical Score

By Trading Central

27.315 / 28.42 Support&Resistance

Short Team

Weak Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

81 / 315 Ranking in Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About Bayer AG

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non